Online Medicine

Product Warranty

Payment Methods

payment-logo

About the Product

Full Description

\n
\n
\n
\n
\n
Tranexamic acid is an antifibrinolytic agent, which competitively inhibits the activation of plasminogen to plasmin.
\n
\n
\n
\n
\n
\n
\n
\n \n
Hemostat Capsule: Each capsule contains Tranexamic Acid BP 500 mg. Hemostat Injection: Each 5 ml ampoule contains Tranexamic Acid BP 250 mg.
\n
\n
\n
\n \n
Short-term use for haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. 1. Local fibrinolysis occurs in the following conditions: Prostatectomy and bladder surgery, Menorrhagia, Epistaxis ,Conisation of the cervix,Traumatic hyphaema, Management of dental extraction patient with coagulopathies, Ulcerative colitis, Hematuria & Gastrointestinal haemorrhage. 2. General fibrinolysis as in prostatic and pancreatic cancer; after thoracic and other major surgery; in obstetrical complication such as abruptio placenta and post-partum haemorrhage; in leukemia and liver diseases and in connection with thrombolytic therapy with streptokinase. 3. Hereditary angioneurotic oedema
\n
\n
\n
\n \n
By mouth: 15-25 mg / kg 2-3 times daily, Menorrhagia 1 g three times daily for up to 4 days; max. 4 g daily, Hereditary angioedema, 1-1.5 g 2-3 times daily. By slow intravenous injection: local fibronolysis, 0.5-1 g 3 times daily.
\n
\n
\n
\n \n
Hemostat is contra-indicated in patients with history of thromboembolic disease and severe renal impairment.
\n
\n
\n
\n \n
Patients with irregular menstrual bleeding should not use Tranexamic Acid until the cause of the irregularity has been established. Patients with a high risk for thrombosis history should use Tranexamic Acid only if there is a strong medical indication and under strict medical supervision.
\n
\n
\n
\n \n
GI discomfort like nausea, vomiting, diarrhoea is common. But disappeared when dosage is reduced. Disturbances in color vision and thromboembolic events reported rarely; giddiness on rapid intravenous injection.
\n
\n
\n
\n \n
Use in pregnancy: Although there is no evidence from animal studies of teratogenic effect, the usual caution with the use of drugs in pregnancy should be observed. Use in lactation: Tranexamic acid is excreted into breast milk, but it is not likely to influence the child at therapeutic doses.
\n
\n
\n
\n \n
Hemostat Capsule: Each box contains 20's capsule in blister pack. Hemostat Injection: Each box contains 5's ampoules.
\n
\n
\n
\n
\n
\n
\n

Reviews:


No Review



Cart

0 Items

0
Cart 0 Item
close
close

Your purchase will delivered in 1 shipment

Express delivery
Empty

Your shopping bag is empty. Start shopping now.